Selvita S.A. opublikuje najnowsze wyniki programu onkologicznego inhibitorów MNK1/2 na Third AACR International Conference on Frontiers in Basic Cancer Research
TitleFile
Raport bieżący EBI 17/2013
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.OkPrivacy policy